BACKGROUND: Vaccination for the 2009 pandemic did not occur until late in the outbreak, which limited its benefits. Influenza A (H7N9) is causing increasing morbidity and mortality in China, and researchers have modified the A (H5N1) virus to transmit via aerosol, which again heightens concerns about pandemic influenza preparedness. OBJECTIVE: To determine how quickly vaccination should be completed to reduce infections, deaths, and health care costs in a pandemic with characteristics similar to influenza A (H7N9) and A (H5N1). DESIGN: Dynamic transmission model to estimate health and economic consequences of a severe influenza pandemic in a large metropolitan city. DATA SOURCES: Literature and expert opinion. TARGET POPULATION: Residents of a U.S. metropolitan city with characteristics similar to New York City. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Vaccination of 30% of the population at 4 or 6 months. OUTCOME MEASURES: Infections and deaths averted and cost-effectiveness. RESULTS OF BASE-CASE ANALYSIS: In 12 months, 48 254 persons would die. Vaccinating at 9 months would avert 2365 of these deaths. Vaccinating at 6 months would save 5775 additional lives and $51 million at a city level. Accelerating delivery to 4 months would save an additional 5633 lives and $50 million. RESULTS OF SENSITIVITY ANALYSIS: If vaccination were delayed for 9 months, reducing contacts by 8% through nonpharmaceutical interventions would yield a similar reduction in infections and deaths as vaccination at 4 months. LIMITATION: The model is not designed to evaluate programs targeting specific populations, such as children or persons with comorbid conditions. CONCLUSION: Vaccination in an influenza A (H7N9) pandemic would need to be completed much faster than in 2009 to substantially reduce morbidity, mortality, and health care costs. Maximizing non-pharmaceutical interventions can substantially mitigate the pandemic until a matched vaccine becomes available. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality, National Institutes of Health, and Department of Veterans Affairs.
BACKGROUND: Vaccination for the 2009 pandemic did not occur until late in the outbreak, which limited its benefits. Influenza A (H7N9) is causing increasing morbidity and mortality in China, and researchers have modified the A (H5N1) virus to transmit via aerosol, which again heightens concerns about pandemic influenza preparedness. OBJECTIVE: To determine how quickly vaccination should be completed to reduce infections, deaths, and health care costs in a pandemic with characteristics similar to influenza A (H7N9) and A (H5N1). DESIGN: Dynamic transmission model to estimate health and economic consequences of a severe influenza pandemic in a large metropolitan city. DATA SOURCES: Literature and expert opinion. TARGET POPULATION: Residents of a U.S. metropolitan city with characteristics similar to New York City. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Vaccination of 30% of the population at 4 or 6 months. OUTCOME MEASURES: Infections and deaths averted and cost-effectiveness. RESULTS OF BASE-CASE ANALYSIS: In 12 months, 48 254 persons would die. Vaccinating at 9 months would avert 2365 of these deaths. Vaccinating at 6 months would save 5775 additional lives and $51 million at a city level. Accelerating delivery to 4 months would save an additional 5633 lives and $50 million. RESULTS OF SENSITIVITY ANALYSIS: If vaccination were delayed for 9 months, reducing contacts by 8% through nonpharmaceutical interventions would yield a similar reduction in infections and deaths as vaccination at 4 months. LIMITATION: The model is not designed to evaluate programs targeting specific populations, such as children or persons with comorbid conditions. CONCLUSION: Vaccination in an influenza A (H7N9) pandemic would need to be completed much faster than in 2009 to substantially reduce morbidity, mortality, and health care costs. Maximizing non-pharmaceutical interventions can substantially mitigate the pandemic until a matched vaccine becomes available. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality, National Institutes of Health, and Department of Veterans Affairs.
Authors: Allison E Aiello; Genevra F Murray; Vanessa Perez; Rebecca M Coulborn; Brian M Davis; Monica Uddin; David K Shay; Stephen H Waterman; Arnold S Monto Journal: J Infect Dis Date: 2010-02-15 Impact factor: 5.226
Authors: Benjamin J Cowling; Kwok-Hung Chan; Vicky J Fang; Calvin K Y Cheng; Rita O P Fung; Winnie Wai; Joey Sin; Wing Hong Seto; Raymond Yung; Daniel W S Chu; Billy C F Chiu; Paco W Y Lee; Ming Chi Chiu; Hoi Che Lee; Timothy M Uyeki; Peter M Houck; J S Malik Peiris; Gabriel M Leung Journal: Ann Intern Med Date: 2009-08-03 Impact factor: 25.391
Authors: Neil M Ferguson; Derek A T Cummings; Christophe Fraser; James C Cajka; Philip C Cooley; Donald S Burke Journal: Nature Date: 2006-04-26 Impact factor: 49.962
Authors: T L Fuller; M F Ducatez; K Y Njabo; E Couacy-Hymann; A Chasar; G L Aplogan; S Lao; F Awoume; A Téhou; Q Langeois; S Krauss; T B Smith Journal: Epidemiol Infect Date: 2014-12-22 Impact factor: 4.434
Authors: Rubina F Rizvi; Kelly J Thomas Craig; Rezzan Hekmat; Fredy Reyes; Brett South; Bedda Rosario; William J Kassler; Gretchen P Jackson Journal: SAGE Open Med Date: 2021-06-06
Authors: Felipe J Colón-González; Iain R Lake; Roger A Morbey; Alex J Elliot; Richard Pebody; Gillian E Smith Journal: BMC Public Health Date: 2018-04-24 Impact factor: 3.295
Authors: Lianci Peng; Wenjuan Du; Melanie D Balhuizen; Henk P Haagsman; Cornelis A M de Haan; Edwin J A Veldhuizen Journal: Front Microbiol Date: 2020-03-19 Impact factor: 5.640